Exella GmbH & Co. KG (manufacturing, primary and secondary packaging, quality control and batch release)
UkraineAll drugs from this manufacturer
-
It is used to treat adults with locally advanced or metastatic HER2-negative breast cancer if the patient has a specific BRCA gene mutation.
Dosage form: capsules
Active substance Dosage talazoparib 0.25 mg ATC: L01XX60
-
The drug is intended for the treatment of adult patients with locally advanced or metastatic HER2-negative breast cancer who have been identified with a pathogenic or likely pathogenic BRCA gene mutation.
Dosage form: capsules
Active substance Dosage talazoparib 1 mg ATC: L01XX60